Saturday 17 October 2026
Export CLRB’s income statement to Excel — free account
Cellectar Biosciences, Inc.
CLRB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 83.2% and free cash flow fell 17.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.14
0.05
−4.20%
Follow CLRB
Cellectar Biosciences, Inc. (CLRB) P/E ratio
Cellectar Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 1.8× (October 2016) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 1.8×
Ten-year median
0.0×
Current reading's percentile
98
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KPRX Kiora Pharmaceuticals, Inc. compare | n/m |
| INTS Intensity Therapeutics Inc. compare | n/m |
| CLRB Cellectar Biosciences, Inc. | n/m |
| PTN Palatin Technologies, Inc. compare | n/m |
| PHIO Phio Pharmaceuticals Corp. compare | n/m |
| ENSC Ensysce Biosciences, Inc. compare | n/m |
| TPST Tempest Therapeutics, Inc. compare | n/m |
| INAB IN8bio, Inc. compare | n/m |
| PASG Passage Bio, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)